Krystal Biotech, Inc. KRYS
345.82
0.86
0.25%
as of 25 Sep
- Market cap
- $10.2B
- P/E
- 41.9×
Follow KRYS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.62 | 34.82 | 33.33 | 44.94 |
P/S ratio |
13.70 | 18.34 | 18.13 | 24.92 | |
P/FCF ratio |
30.79 | 37.69 | 31.87 | 42.57 | |
P/Operating CF |
128.88 | 92.07 | 94.12 | 146.75 | |
P/B ratio |
4.49 | 5.85 | 5.93 | 8.08 | |
Price to Tangible BV |
4.49 | 5.85 | 5.93 | 8.08 | |
EV/Sales |
11.74 | 16.21 | 16.16 | 23.00 | |
EV/EBITDA |
26.58 | 37.58 | 36.37 | 49.55 | |
EV/Operating CF |
24.86 | 31.40 | 26.94 | 37.19 | |
EV/FCF |
26.38 | 33.31 | 28.40 | 39.29 | |
Quick Ratio |
9.43 | 9.28 | 8.82 | 7.73 | |
Current Ratio |
10.14 | 9.95 | 9.46 | 8.32 | |
Net Debt/EBITDA |
(17.01) | (17.98) | (14.86) | (14.10) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.34 | 0.33 | 0.34 | 0.33 | |
Operating CF/Net income |
0.50 | 1.51 | 1.44 | 1.37 | |
Capex/Depreciation |
(1.06) | (1.21) | (4.14) | (2.28) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14.91% | 13.81% | 13.18% | 12.18% | |
Selling, General and Administrative Expense of Revenue |
38.42% | 38.70% | 35.25% | 33.43% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.45% | 12.85% | 11.70% | 11.87% | |
Graham Net Nets |
0.16 | 0.13 | 0.12 | 0.08 | |
Graham Number |
78.06 | 81.93 | 87.19 | 92.54 | |
Earnings Yield |
3.90% | 2.87% | 3.00% | 2.23% | |
Free Cash Flow Yield |
3.25% | 2.65% | 3.14% | 2.35% | |
Revenue per Share |
3.38 | 3.70 | 3.97 | 4.04 | |
Operating CF per Share |
1.37 | 2.68 | 2.74 | 2.53 | |
Capex per Share |
(0.06) | (0.07) | (0.24) | (0.12) | |
Free Cash Flow per Share |
1.31 | 2.60 | 2.50 | 2.41 | |
Cash per Share |
25.25 | 28.60 | 28.11 | 28.64 | |
Shareholders Equity per Share |
39.30 | 42.14 | 43.59 | 46.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
39.30 | 42.14 | 43.59 | 46.03 | |
Free Cash Flow |
37.96 | 75.37 | 73.23 | 71.22 | |
Working Capital |
834.38 | 921.66 | 911.94 | 932.25 | |
Capital Expenditures |
(1.70) | (2.14) | (7.15) | (3.56) | |
Net Current Asset Value |
823.43 | 910.37 | 899.50 | 918.13 | |
EV/EBIT |
27.65 | 39.11 | 37.72 | 51.22 | |
Capex to Sales |
0.02 | 0.02 | 0.06 | 0.03 | |
Net Profit Margin |
81.15% | 47.99% | 48.07% | 45.94% | |
Price to Operating Income |
32.26 | 44.24 | 42.33 | 55.50 | |
| Other line items | |||||
Average Receivables |
113.47 | 116.09 | 115.14 | 125.05 | |
Average Payables |
3.84 | 4.11 | 3.38 | 6.83 | |
Average Inventory |
28.11 | 33.49 | 36.29 | 38.30 | |
Average Assets |
1,111.21 | 1,194.82 | 1,235.69 | 1,319.52 | |
Average Common Equity |
1,011.86 | 1,082.97 | 1,130.70 | 1,199.89 |
Columns are period end dates